AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23153149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media messages (thematic mediators: selection, pleasure, and negotiation)
Number of subjects: 1139
Study 23153149 — intervention group
Group type: COMPARATOR
Intervention: Mass media exposure
Number of subjects: 1139
Study 22164968 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated azithromycin powder for suspension (Tridosil 200 mg/5 ml)
Number of subjects: 24
Study 22164968 — intervention group
Group type: COMPARATOR
Intervention: Uncoated azithromycin powder for suspension (200 mg/5 ml)
Number of subjects: 24
Study 19896041 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-enriched gel
Number of subjects: 100
Study 19896041 — intervention group
Group type: COMPARATOR
Intervention: Non-gel group
Number of subjects: 100
Study 16953150 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 32
Study 16953150 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 32
Study 21067346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg once daily)
Number of subjects: 68
Study 21067346 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (20 mg once daily)
Number of subjects: 68
Study 10394450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral saccharose administration
Number of subjects: 37
Study 10394450 — intervention group
Group type: COMPARATOR
Intervention: Water administration
Number of subjects: 37
Study 8707972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg q.i.d. plus scaling
Number of subjects: 30
Study 8707972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg q.i.d. alone
Number of subjects: 30
Study 8707972 — intervention group
Group type: COMPARATOR
Intervention: Scaling plus placebo q.i.d.
Number of subjects: 30
Study 8707972 — intervention group
Group type: COMPARATOR
Intervention: Placebo q.i.d. alone
Number of subjects: 30
Study 1649971 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (40 mg/kg IV every 8 hours)
Number of subjects: 14
Study 1649971 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine (15 mg/kg IV per day)
Number of subjects: 14
Study 1649971 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 14
Study 1649971 — intervention group
Group type: COMPARATOR
Intervention: Vidarabine
Number of subjects: 14
Study 6341914 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% solution of fenoprofen sodium
Number of subjects: 14
Study 6341914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30963330 — intervention group
Group type: EXPERIMENTAL
Intervention: Myths vs. facts booklet
Number of subjects: 60
Study 30963330 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 60
Study 30236110 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 mg)
Number of subjects: 16
Study 30236110 — intervention group
Group type: COMPARATOR
Intervention: Inhaled saline (4 ml)
Number of subjects: 16
Study 29231358 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulating Conception‐Governor Vessel acupuncture method
Number of subjects: 100
Study 29231358 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (50 mg per day for 5 consecutive days)
Number of subjects: 100
Study 24640990 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 × 1000 mg rituximab
Number of subjects: 22
Study 24640990 — intervention group
Group type: COMPARATOR
Intervention: 2 × 500 mg rituximab
Number of subjects: 22
Study 22946762 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.25 μg/kg/h for 24 h)
Number of subjects: 90
Study 22946762 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 90
Study 22946762 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion
Number of subjects: 90
Study 19164398 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual environment training (5 one-hour sessions)
Number of subjects: 13
Study 19164398 — intervention group
Group type: COMPARATOR
Intervention: Attention control training (5 one-hour sessions)
Number of subjects: 13
Study 17137561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of 24 IU oxytocin
Number of subjects: 30
Study 17137561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17069221 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 0
Study 17069221 — intervention group
Group type: COMPARATOR
Intervention: Insulin injections
Number of subjects: 0
Study 12517044 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (containing antigens B/Yamanashi/166/98, A/New Caledonia/20/99 (H1N1), and A/Panama/2007/99 (H3N2))
Number of subjects: 65
Study 12517044 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 65
Study 9753207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dolasetron mesylate (200 mg)
Number of subjects: 36
Study 9753207 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dolasetron mesylate (200 mg)
Number of subjects: 36
Study 9753207 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of hydrodolasetron and its metabolites
Number of subjects: 36
Study 9753207 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 36
Study 9753207 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 36
Study 7826913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mx 2% topical solution
Number of subjects: 48
Study 7826913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3042005 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (3 grams intravenously in a 60 ml solution, repeated 6 times with 12-hour intervals)
Number of subjects: 140
Study 3042005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31655378 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI+CBT (escitalopram 20 mg daily, 10 mg first week)
Number of subjects: 47
Study 31655378 — intervention group
Group type: COMPARATOR
Intervention: Placebo+CBT
Number of subjects: 47
Study 30955982 — intervention group
Group type: EXPERIMENTAL
Intervention: LBRV-PV (Liquid Bovine-Human Reassortant Pentavalent Vaccine)
Number of subjects: 1500
Study 30955982 — intervention group
Group type: COMPARATOR
Intervention: Rotasiil® (Lyophilized Bovine-Human Rotavirus Reassortant Pentavalent Vaccine)
Number of subjects: 1500
Study 30955982 — intervention group
Group type: EXPERIMENTAL
Intervention: LBRV-PV Lot A
Number of subjects: 1500
Study 30955982 — intervention group
Group type: EXPERIMENTAL
Intervention: LBRV-PV Lot B
Number of subjects: 1500
Study 28919716 — intervention group
Group type: EXPERIMENTAL
Intervention: RDX7675 (reconstituted in water)
Number of subjects: 0
Study 28919716 — intervention group
Group type: EXPERIMENTAL
Intervention: RDX7675 (high-viscosity vanilla)
Number of subjects: 0
Study 28919716 — intervention group
Group type: COMPARATOR
Intervention: Sodium polystyrene sulfonate (SPS)
Number of subjects: 0
Study 24192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic assessment, nutrition intervention and follow‐up in addition to regular community hospital interface programme support (Intervention group, n=9)
Number of subjects: 24
Study 24192128 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment from community hospital interface programme nursing staff (Control group, n=10)
Number of subjects: 24
Study 24192128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic assessment, nutrition intervention and follow‐up (Intervention group)
Number of subjects: 24
Study 23611572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric formulation of bosentan (64 mg as 2 pediatric tablets of 32 mg)
Number of subjects: 16
Study 23611572 — intervention group
Group type: COMPARATOR
Intervention: Adult formulation of bosentan (62.5 mg as 1 adult tablet)
Number of subjects: 16
Study 21561527 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg) + Ibuprofen (400 mg)
Number of subjects: 0
Study 21561527 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1,000 mg)
Number of subjects: 0
Study 21561527 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (325 mg) + Codeine (30 mg)
Number of subjects: 0
Study 19136749 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (3 mg/kg)
Number of subjects: 82
Study 19136749 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 82
Study 17370497 — intervention group
Group type: EXPERIMENTAL
Intervention: Surround needling plus surround moxibustion
Number of subjects: 72
Study 17370497 — intervention group
Group type: COMPARATOR
Intervention: Surround needling (control)
Number of subjects: 72
Study 15209182 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scan
Number of subjects: 118
Study 15209182 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 118
Study 11355042 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral micronized E2 daily for 16 months
Number of subjects: 33
Study 11355042 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 delivered at a rate of 0.05 mg/day
Number of subjects: 33
Study 11355042 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 delivered at a rate of 0.1 mg/day
Number of subjects: 33
Study 11355042 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch for 9 months
Number of subjects: 33
Study 9150323 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation of bronchitis (E)
Number of subjects: 13
Study 9150323 — intervention group
Group type: COMPARATOR
Intervention: Chronic bronchitis patients
Number of subjects: 13
Study 8035241 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated management approach for postdate pregnancy
Number of subjects: 0
Study 3109581 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive consultation (with treatment)
Number of subjects: 200
Study 3109581 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive consultation (without treatment)
Number of subjects: 200
Study 3109581 — intervention group
Group type: COMPARATOR
Intervention: Negative consultation (with treatment)
Number of subjects: 200
Study 3109581 — intervention group
Group type: COMPARATOR
Intervention: Negative consultation (without treatment)
Number of subjects: 200
Study 3109581 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated group (positive or negative consultation)
Number of subjects: 200
Study 3109581 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (positive or negative consultation)
Number of subjects: 200
Study 2550696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg/day)
Number of subjects: 12
Study 2550696 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg/day)
Number of subjects: 12
Study 2550696 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg/day)
Number of subjects: 12
Study 31182142 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the aseptic practice bundle
Number of subjects: 10000
Study 31182142 — intervention group
Group type: COMPARATOR
Intervention: Aseptic practice observation
Number of subjects: 10000
Study 28190152 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia primary crowns
Number of subjects: 56
Study 28190152 — intervention group
Group type: COMPARATOR
Intervention: Cobalt‐chromium alloy primary crowns
Number of subjects: 56
Study 25770419 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Control exercises (MC)
Number of subjects: 106
Study 25770419 — intervention group
Group type: COMPARATOR
Intervention: General Exercise (GE)
Number of subjects: 106
Study 23965158 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis skin lesions
Number of subjects: 89
Study 23965158 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis serum
Number of subjects: 89
Study 21831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg/HCT 12.5 mg
Number of subjects: 253
Study 21831438 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 16 mg monotherapy
Number of subjects: 253
Study 21831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg/HCT 12.5 mg
Number of subjects: 253
Study 21831438 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 32 mg monotherapy
Number of subjects: 253
Study 21831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan-HCT combination therapy
Number of subjects: 253
Study 21831438 — intervention group
Group type: COMPARATOR
Intervention: Candesartan monotherapy
Number of subjects: 253
Study 21831438 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg
Number of subjects: 253
Study 19217077 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day to 150 mg/day)
Number of subjects: 25
Study 19217077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17146377 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 50 mg
Number of subjects: 94
Study 17146377 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 94
Study 17146377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 17146377 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 2.5 mg
Number of subjects: 94
Study 17146377 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 10 mg
Number of subjects: 94
Study 15070225 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct training group
Number of subjects: 55
Study 15070225 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect training group
Number of subjects: 55
Study 15070225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 11314743 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous corticosteroid therapy (1 g of methylprednisolone diluted in 250-500 ml of physiological solution for 6 weeks)
Number of subjects: 51
Study 11314743 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (60-80 mg/day progressively reduced every 2 weeks for a total duration of 4-6 months)
Number of subjects: 51
Study 9467724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum exposure
Number of subjects: 0
Study 9467724 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study 7894895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome patients
Number of subjects: 68
Study 7894895 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 donors)
Number of subjects: 68
Study 2896810 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing chemotherapy (Arm A)
Number of subjects: 125
Study 2896810 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy until morphological relapse (Arm B)
Number of subjects: 125
Study 2896810 — intervention group
Group type: COMPARATOR
Intervention: No further chemotherapy until increase in myeloblast antigens (Arm C)
Number of subjects: 125
Study 2896810 — intervention group
Group type: COMPARATOR
Intervention: Quality of life assessment for arms B and C
Number of subjects: 125
Study 29358464 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 29358464 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 0
Study 26660724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk condition
Number of subjects: 1046
Study 26660724 — intervention group
Group type: COMPARATOR
Intervention: Cultural cognition worldview and negative emotions (sadness and anger)
Number of subjects: 1046
Study 25321621 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifemin (20 mg bid po)
Number of subjects: 116
Study 25321621 — intervention group
Group type: COMPARATOR
Intervention: Tibolone (2.5 mg qd po)
Number of subjects: 116
Study 22770838 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 275
Study 22770838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 275
Study 22770838 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo acupuncture
Number of subjects: 275
Study 22770838 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 275
Study 20028850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (70% O2)
Number of subjects: 7
Study 20028850 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (N)
Number of subjects: 7
Study 18271235 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (48 hours to 1 week after operation) with various acupoints (Neiguan, Qu‐chi, Waiguan, Hegu, Binao, Jianyu, Fengshi, Xuehai, Yinlingquan, Sanyinjiao, Taichong)
Number of subjects: 96
Study 18271235 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of neurosurgical operation and drug treatment (Mannitol, Citioline Sodium, Cefeazidime, etc.)
Number of subjects: 96
Study 15608034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical sodium nitroprusside gel (10 mg)
Number of subjects: 200
Study 15608034 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 200
Study 12798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists
Number of subjects: 0
Study 12798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin substitute
Number of subjects: 0
Study 12798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 12798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation devices and implantable defibrillators
Number of subjects: 0
Study 12798839 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacing
Number of subjects: 0
Study 12798839 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave alternans
Number of subjects: 0
Study 10426873 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 0
Study 10426873 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0
Study 10426873 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 10426873 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting in association with angioplasty
Number of subjects: 0
Study 10426873 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0
Study 10426873 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study 8935242 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor families
Number of subjects: 0
Study 8935242 — intervention group
Group type: COMPARATOR
Intervention: Nonpoor families
Number of subjects: 0
Study 8935242 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model including poverty, race, site, and representative environmental, maternal, and child variables
Number of subjects: 0
Study 8935242 — intervention group
Group type: EXPERIMENTAL
Intervention: Poverty and maternal IQ
Number of subjects: 0
Study 8935242 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal distress
Number of subjects: 0
Study 2010243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (0.5 to 6 micrograms/kg/min)
Number of subjects: 9
Study 2010243 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (5 to 25 micrograms/kg/min)
Number of subjects: 9
Study 2010243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 9
Study 2010243 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 9
Study 2010243 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine and Dobutamine
Number of subjects: 9
Study 7037036 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol nebulized with IPPB (5 mg)
Number of subjects: 0
Study 7037036 — intervention group
Group type: COMPARATOR
Intervention: Rotacaps (2 x 400 micrograms)
Number of subjects: 0
Study 7037036 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol nebulized without IPPB
Number of subjects: 0
Study 31452006 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely Randomized Trees algorithm for identifying follow-up examinations
Number of subjects: 559
Study 31452006 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-annotator agreement among three radiologists
Number of subjects: 559
Study 28985630 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG plus simethicone
Number of subjects: 583
Study 28985630 — intervention group
Group type: COMPARATOR
Intervention: PEG alone
Number of subjects: 583
Study 27121262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 4 mg (normal hepatic function)
Number of subjects: 48
Study 27121262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 2.3 mg (moderate hepatic impairment)
Number of subjects: 48
Study 27121262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib 1.5 mg (severe hepatic impairment)
Number of subjects: 48
Study 27121262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (moderate/severe hepatic impairment combined)
Number of subjects: 48
Study 27121262 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended starting dose for ixazomib
Number of subjects: 48
Study 24277763 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dietary data (food frequency questionnaires, 4-day food records, or three 24-hour dietary recalls)
Number of subjects: 0
Study 24277763 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration equations using food records or recalls
Number of subjects: 0
Study 24277763 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration equations for food frequency questionnaire data
Number of subjects: 0
Study 22780921 — intervention group
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine dimesylate
Number of subjects: 116
Study 22780921 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study 21069115 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised opportunistic chlamydia screening programme with practice education, self-sample collection, and practice incentives for three months.
Number of subjects: 2
Study 21069115 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led screening strategy
Number of subjects: 2
Study 21069115 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor-led screening strategy
Number of subjects: 2
Study 21069115 — intervention group
Group type: COMPARATOR
Intervention: Control practice (no intervention)
Number of subjects: 2